Intervention Review

Dehydroepiandrosterone for systemic lupus erythematosus

  1. David Crosbie1,*,
  2. Corri Black2,
  3. Linda McIntyre3,
  4. Pamela Royle4,
  5. Sian Thomas3

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 17 OCT 2007

Assessed as up-to-date: 29 JUN 2007

DOI: 10.1002/14651858.CD005114.pub2


How to Cite

Crosbie D, Black C, McIntyre L, Royle P, Thomas S. Dehydroepiandrosterone for systemic lupus erythematosus. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD005114. DOI: 10.1002/14651858.CD005114.pub2.

Author Information

  1. 1

    Aberdeen Royal Infirmary, Department of Rheumatology, Aberdeen, UK

  2. 2

    University of Aberdeen, Department of Public Health, Aberdeen, Scotland, UK

  3. 3

    c/o University of Aberdeen, Aberdeen, UK

  4. 4

    University of Aberdeen, School of Medicine, Department of Public Health, Aberdeen, UK

*David Crosbie, Department of Rheumatology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, AB25, UK. David.Crosbie@sgh.scot.nhs.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 17 OCT 2007

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Mordechai Slae, Merav Heshin-Bekenstein, Ari Simckes, Gali Heimer, Dan Engelhard, Eli M. Eisenstein, Female polysomy-X and systemic lupus erythematosus, Seminars in Arthritis and Rheumatism, 2014, 43, 4, 508

    CrossRef

  2. 2
    Sara K. Tedeschi, Bonnie Bermas, Karen H. Costenbader, Sexual disparities in the incidence and course of SLE and RA, Clinical Immunology, 2013, 149, 2, 211

    CrossRef

  3. 3
    George Bertsias, Antonios Fanouriakis, Dimitrios T. Boumpas, Kelley's Textbook of Rheumatology, 2013,

    CrossRef

  4. 4
    Ellen M. Ginzler, David Wofsy, David Isenberg, Caroline Gordon, Laura Lisk, Mary-Anne Dooley, Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: Findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial, Arthritis & Rheumatism, 2010, 62, 1